Test tube

Novel gene therapy could reduce bleeding risk for haemophilia patients

21 July 2022 | Spinout News

For the paper, published in the New England Journal of Medicine, experts from UCL, Royal Free Hospital and biotechnology company Freeline Therapeutics trialled and continue to evaluate a new type of adeno-associated virus (AAV) gene therapy candidate, called FLT180a, to treat severe and moderately severe cases of the condition.

Professor Geraint Rees (UCL Vice-Provost Research, Innovation and Global Engagement, and Non-Executive Director of UCL Business), said: “The results of this important study are a perfect example of how UCL research and innovation can translate to real-world and life-changing impact.”

Freeline logo

The Phase I/II trial was sponsored by UCL and funded by Freeline Therapeutics.

Freeline was supported by UCL Business (UCLB), UCL’s commercialisation company.

Read the full story here.